retatrutide phase 3 2025 triple agonist glp-1 gip glucagon ✨ Retatrutide: The Next Evolution in Weight Loss Medications ✨ You may be hearing the informal term “GLP-3” — but what does that actually mean? is a new triple-agonist medication that retatrutide triple agonist glp-1 gip

Haykal D (2025)

For Type 2 diabetes patients with adequate beta cell function, GLP-1 medications can sometimes replace or delay the need for insulin therapy

After exercise, the body is more responsive to nutrients a well-balanced meal with protein, fiber, and healthy fats during this post-workout window may further stimulate GLP-1 and support appetite regulation and metabolic health

Im now seeing results after almost a year of treatment

Our patients enjoy falling asleep more quickly, staying asleep, and heightened wellness with regular DSIP use

Understanding the broad mechanism of action is essential when considering whether GLP-1 medications might influence hormonal balance more generally, particularly given their increasing use in diverse patient populations including those with metabolic syndrome, polycystic ovary syndrome (PCOS), and obesity-related endocrine dysfunction